Research output
- 7 Article
-
Simultaneous auto-transplant and CD19 CAR T-cell 2nd line therapy followed by CD20 × CD3 bispecific antibody for refractory Burkitt lymphoma, a case report
Stegemann, M., Macherndl-Spandl, S., Mairhofer, M., Kaltenbrunner, S., Buxhofer-Ausch, V., Clausen, J., Petzer, A. & Schmitt, C. A., Apr 2026, In: Leukemia and Lymphoma. 67, 5, p. 1147-1151 5 p.Research output: Contribution to journal › Article › peer-review
-
Cell-based immune anticipation of the omicron variant in SARS-CoV-2 triple-vaccinated cancer patients
Mairhofer, M., Kausche, L., Kaltenbrunner, S., Pammer, M., Ghanem, R., Stegemann, M. & Schmitt, C. A., 21 Nov 2025, In: iScience. 28, 11, 113727.Research output: Contribution to journal › Article › peer-review
Open Access -
Erratum: Cell-based immune anticipation of the omicron variant in SARS-CoV-2 triple-vaccinated cancer patients (iScience (2025) 28(11), (S2589004225019881), (10.1016/j.isci.2025.113727))
Mairhofer, M., Kausche, L., Kaltenbrunner, S., Pammer, M., Ghanem, R., Stegemann, M. & Schmitt, C. A., 21 Nov 2025, In: iScience. 28, 11, 113890.Research output: Contribution to journal › Article › peer-review
Open Access -
DLBCL 1L-What to Expect beyond R-CHOP?
Stegemann, M., Denker, S. & Schmitt, C., 11 Mar 2022, In: Cancers. 14, 6, 1 p., 1453.Research output: Contribution to journal › Article › peer-review
Open Access -
ASH 2020 Highlights zu den aggressiven Non-Hodgkin Lymphomen
Schmitt, C. & Stegemann, M., Feb 2021, In: Spectrum Onkologie. 1 p.Research output: Contribution to journal › Article
-
ABCSG61 Teodor
Stegemann, M. (Researcher), Kausche, L. E. (Researcher), Lichtenauer, N. (Researcher), Popp, H. D. (Researcher), Schwarz, H. K. (Researcher), Kühr, T. (Researcher), Schneeweiß, B. (Researcher), Ghanem, R. (Researcher), Schmitt, C. (Researcher), Preuß, C. (Researcher), Piringer, G. (Researcher), Stefan, A. (Researcher) & Kovacsova, J. (Researcher)
03.03.2026 → 02.09.2028
Project: Clinical studies › Clinical Study (Industry project)
-
Camelot-2
Popp, H. (Researcher), Lichtenauer, N. (Researcher), Kausche, L. E. (Researcher), Stegemann, M. (Researcher), Ghanem, R. (Researcher), Schneeweiß, B. (Researcher), Schmitt, C. (Researcher), Schwarz, H. K. (Researcher), Piringer, G. (Researcher), Kovacsova, J. (Researcher), Stefan, A. (Researcher) & Kühr, T. (Researcher)
01.12.2025 → 31.12.2029
Project: Clinical studies › Clinical Study (Industry project)
-
KRT-232-115
Lichtenauer, N. (Researcher), Stegemann, M. (Researcher), Stefan, A. (Researcher), Kausche, L. E. (Researcher), Piringer, G. (Researcher), Ghanem, R. (Researcher), Schmitt, C. (Researcher), Kovacsova, J. (Researcher), Popp, H. (Researcher), Schwarz, H. K. (Researcher), Schneeweiß, B. (Researcher) & Kühr, T. (Researcher)
01.09.2025 → 28.02.2029
Project: Clinical studies › Clinical Study (Industry project)
-
A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo- Controlled, Parallel-Arm Study Followed by an Open-Label Arm to Evaluate the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia (ARGX-113-2402)
Schmitt, C. (PI), Krivic, D. (Researcher), Lichtenauer, N. (Researcher), Kühr, T. (Researcher), Schneeweiß, B. (Researcher), Piringer, G. (Researcher), Popp, H. D. (Researcher), Krenosz, K. J. (Researcher), Ghanem, R. (Researcher), Stefan, A. (Researcher), Schwarz, H. K. (Researcher), Kovacsova, J. (Researcher), Kausche, L. E. (Researcher), Stegemann, M. (Researcher), Klein, K. (Researcher) & Trathnigg, N. (Researcher)
04.06.2025 → 31.05.2029
Project: Clinical studies › Clinical Study (Industry project)
-
Phase III randomized, open-label, international, multicenter study evaluating the efficacy and safety of mosunetuzumab plus lenalidomide in comparison to anti- CD20 monoclonal antibody plus chemotherapy in subjects with previously untreated FLIPI 2-5 follicular lymphoma (MorningLyte)
Schmitt, C. (PI), Krivic, D. (Researcher), Lichtenauer, N. (Researcher), Kühr, T. (Researcher), Schneeweiß, B. (Researcher), Piringer, G. (Researcher), Popp, H. D. (Researcher), Krenosz, K. J. (Researcher), Ghanem, R. (Researcher), Stefan, A. (Researcher), Schwarz, H. K. (Researcher), Kovacsova, J. (Researcher), Kausche, L. E. (Researcher), Stegemann, M. (Researcher), Klein, K. (Researcher) & Trathnigg, N. (Researcher)
02.06.2025 → 31.05.2029
Project: Clinical studies › Clinical Study (Industry project)
-
Bispecific Antibody Activity against Senescent Lymphoma Cells
Stegemann, M. (Speaker)
13 Nov 2025Activity: Talk or presentation › Poster presentation › science-to-science
-
Myeloisch: Kurz und prägnant: Klinisch relevante Veränderungen 2025
Popp, H. (Speaker), Schmitt, C. (Contributor), Stegemann, M. (Speaker), Stefan, A. (Speaker), Rumpold, H. (Contributor), Heibl, S. (Contributor), Clausen, J. (Speaker), Rotter, N. (Speaker), Strassl, I. (Speaker) & Heine, A. (Speaker)
11 Nov 2025Activity: Talk or presentation › Invited talk › science-to-science
-
Lymphom: Unmet clinical need
Stegemann, M. (Speaker), Schmitt, C. (Contributor), Popp, H. (Speaker), Stefan, A. (Speaker), Rumpold, H. (Contributor), Clausen, J. (Speaker), Rotter, N. (Speaker), Strassl, I. (Speaker), Heine, A. (Speaker) & Heibl, S. (Speaker)
11 Nov 2025Activity: Talk or presentation › Invited talk › science-to-science
-
Simultaneous auto-transplant and CD19 CAR T-cell 2L therapy followed by a CD20 x CD3 bispecific antibody in a patient with refractory Burkitt lymphoma
Stegemann, M. (Speaker)
03 Dec 2024Activity: Talk or presentation › Poster presentation › science-to-science
-
T-NHL
Stegemann, M. (Speaker)
01 Nov 2024Activity: Talk or presentation › Contributed talk › science-to-science